1. Academic Validation
  2. Actual status of veralipride use

Actual status of veralipride use

  • Clin Interv Aging. 2010 Sep 7;5:271-6. doi: 10.2147/cia.s12640.
Sebastián Carranza-Lira 1
Affiliations

Affiliation

  • 1 Reproductive Medicine Service. Hospital de Ginecología y Obstetricia Luis Castelazo Ayala Instituto Mexicano del Seguro Social, México DF. scarranzal@mexis.com
Abstract

During the climacteric period, several symptoms exist that motivate women to seek medical advice; one of the most common is the hot flush, which presents in 75%-85% of these during a variable time span. For the treatment of hot flush, several non-hormonal treatments exist; among them, veralipride has shown to be a useful treatment of vasomotor symptoms during the climacteric period. In recent times, several medical societies have discredited its use. The purpose of this review, therefore, is to define a measured position in relation to the use of this drug. On completion of this review, it was possible to conclude that this drug has an antidopaminergic mechanism of action. The recommended schedule is: 100 mg/day for 20 days, with 10 days drug free. Since the risk of undesirable secondary effects such as galactorrhea, mastodynia, and extrapyramidal can increase with use, no more than 3 treatment cycles are recommended. This drug has a residual effect that can allow drug-free intervals, which permit a longer time between schedules.

Keywords

climacteric; hot flushes; menopause; secondary effects; symptoms; veralipride.

Figures
Products